Baxter (BAX) Q2 Revenue Rises 4%
Baxter International (NYSE:BAX), a leading global provider of medical products and connected care solutions, released its second-quarter earnings on July 31, 2025. The company reported GAAP revenue of $2.81 billion and adjusted earnings per share (EPS) of $0.59, both just shy of consensus estimates of $2.82 billion (GAAP revenue) and $0.61 (non-GAAP EPS), respectively. Despite this modest shortfall, both revenue and earnings showed solid improvement compared to the prior year quarter. The quarter was marked by better adjusted operating margins, stable segment performance, and ongoing efforts to optimize the company's portfolio and reduce debt. Management reaffirmed its commitment to innovation but maintained a cautious financial outlook for the remainder of FY2025, tightening full-year guidance in light of headwinds in key business lines.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Baxter International is a diversified healthcare company offering products such as infusion pumps, IV solutions, hospital pharmaceuticals, and digital health systems. Its core business is split among three main segments: Medical Products Therapies (hospital products like IV fluids and infusion systems), Healthcare Systems Technologies (connected care solutions and vital sign monitoring devices), and Pharmaceuticals (injectable medicines and compounding solutions).
Source Fool.com
